Mol Med Rep:YAP敲除能够抑制人类前列腺癌DU145细胞的增殖和诱导其凋亡

2018-01-19 AlexYang MedSci原创

最近,有研究人员探究了YAP蛋白在人类前列腺癌DU145细胞中的角色和它的潜在的分子机制。研究人员起始时检测了YAP在DU145细胞中的表达水平,并且阐释了YAP在这些细胞中具有高水平的表达。为了调查YAP在DU145细胞中的角色,研究人员利用YAP小干扰RNA产生了一个稳定的YAP沉默的DU145细胞系,还利用RT-PCR技术和蛋白免疫技术分别检测了mRNA和蛋白。另外,研究人员还利用了MTT实

最近,有研究人员探究了YAP蛋白在人类前列腺癌DU145细胞中的角色和它的潜在的分子机制。研究人员起始时检测了YAP在DU145细胞中的表达水平,并且阐释了YAP在这些细胞中具有高水平的表达。为了调查YAP在DU145细胞中的角色,研究人员利用YAP小干扰RNA产生了一个稳定的YAP沉默的DU145细胞系,还利用RT-PCR技术和蛋白免疫技术分别检测了mRNA和蛋白。另外,研究人员还利用了MTT实验和流式细胞仪调查了DU145细胞的增殖和凋亡情况。

研究结果表明,与对照相比,YAP的敲除能够显著的降低DU145细胞的增殖能力,然而凋亡细胞的比例显著的增加。另外,结缔组织生长因子和富含半胱氨酸的血管生成因子61的mRNA和蛋白表达水平明显的降低,并且B细胞淋巴瘤(Bcl-2)/ Bcl-2相关的X蛋白(Bax)显著的减少,细胞凋亡蛋白酶3的表达水平在YAP沉默的DU145细胞中显著减少。最后,研究人员指出,YAP的敲除能够减少DU145细胞的增殖,并且诱导其凋亡。因此,YAP的转录和蛋白表达也许参与了前列腺癌的发展,应该考虑作为治疗这些癌症的潜在靶标。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2081886, encodeId=1eae2081886e9, content=<a href='/topic/show?id=c2971893397' target=_blank style='color:#2F92EE;'>#YAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18933, encryptionId=c2971893397, topicName=YAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Mon Apr 30 03:39:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608460, encodeId=fe051608460cb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 21 12:39:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280389, encodeId=c6a7280389dd, content=谢谢.学习受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sat Jan 20 15:21:28 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280161, encodeId=c3f4280161f7, content=是很好的学习材料.不错.以后会多学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Jan 19 22:02:03 CST 2018, time=2018-01-19, status=1, ipAttribution=)]
    2018-04-30 gujh
  2. [GetPortalCommentsPageByObjectIdResponse(id=2081886, encodeId=1eae2081886e9, content=<a href='/topic/show?id=c2971893397' target=_blank style='color:#2F92EE;'>#YAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18933, encryptionId=c2971893397, topicName=YAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Mon Apr 30 03:39:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608460, encodeId=fe051608460cb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 21 12:39:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280389, encodeId=c6a7280389dd, content=谢谢.学习受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sat Jan 20 15:21:28 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280161, encodeId=c3f4280161f7, content=是很好的学习材料.不错.以后会多学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Jan 19 22:02:03 CST 2018, time=2018-01-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2081886, encodeId=1eae2081886e9, content=<a href='/topic/show?id=c2971893397' target=_blank style='color:#2F92EE;'>#YAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18933, encryptionId=c2971893397, topicName=YAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Mon Apr 30 03:39:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608460, encodeId=fe051608460cb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 21 12:39:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280389, encodeId=c6a7280389dd, content=谢谢.学习受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sat Jan 20 15:21:28 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280161, encodeId=c3f4280161f7, content=是很好的学习材料.不错.以后会多学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Jan 19 22:02:03 CST 2018, time=2018-01-19, status=1, ipAttribution=)]
    2018-01-20 清风拂面

    谢谢.学习受益匪浅

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2081886, encodeId=1eae2081886e9, content=<a href='/topic/show?id=c2971893397' target=_blank style='color:#2F92EE;'>#YAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18933, encryptionId=c2971893397, topicName=YAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Mon Apr 30 03:39:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608460, encodeId=fe051608460cb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 21 12:39:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280389, encodeId=c6a7280389dd, content=谢谢.学习受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sat Jan 20 15:21:28 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280161, encodeId=c3f4280161f7, content=是很好的学习材料.不错.以后会多学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Jan 19 22:02:03 CST 2018, time=2018-01-19, status=1, ipAttribution=)]
    2018-01-19 李东泽

    是很好的学习材料.不错.以后会多学习.

    0

相关资讯

Lancet Oncol:无症状转移性去势抵抗性前列腺癌:双相雄激素治疗有效

美国约翰·霍普金斯大学医学院Teply等在Lancet Oncol.上发表了一篇关于前列腺癌双相雄激素治疗(BAT)的论文。

Proteomes:尿液比较蛋白组学分析阐释了急性期反应信号和LXR/RXR激活通路在前列腺癌中下调

利用非侵入型诊断标记来检测前列腺癌(PCa)仍旧是一种挑战。最近,有研究人员对尿蛋白进行了鉴定,旨在鉴定出能够在早期阶段对PCa具有足够敏感性和特异性检测的尿蛋白。研究人员对患有PCa、良性前列腺增生、膀胱癌和肾癌的病人,结合生物信息学分析,进行了尿液的比较蛋白组学分析。研究发现,在2-D DIGE/MS和无标签LC-MS/MS实验中,分别有20个和85个蛋白在丰度上具有统计学显著差异。信息学分析

Clin Chem:循环肿瘤细胞中AR-V7, AR-FL, PSA和KRAS位点点突变的原位检测和定量

液体活检可以在去势难治性前列腺癌(CRPC)中检测雄激素受体剪接变异体7(AR-V7),一种雄激素受体的剪接产物。患有AR-V7阳性循环肿瘤细胞(CTCs)的病人在紫杉烷化疗方面要比新激素治疗效果更好,表明了一种治疗选择性生物标记。同样的,在那些患有胰腺癌(PaCa)的病人中,KRAS变异可以作为预后生物标记。因此,对CTCs的表达和变异情况的调查的技术是迫切需要的。最近,有研究人员报道了将AR-

Brit J Cancer:在前瞻性前列腺癌筛选研究中,具有遗传易感性男性前列腺特异性抗原速度分析

前列腺特异性抗原(PSA)和PSA速度(PSAV)已经被用来鉴定具有前列腺癌风险(PrCa)的男性。IMPACT研究评估了PSA筛选,具体是在由于BRCA1/2的变异而具有PrCa遗传易感性的男性中进行。最近,有研究人员评估了在上述群体中,PSA和PSAV在鉴定PrCa和高等级疾病中的利用。研究人员利用逻辑回归计算了PSAV从而来确定是否PSA或者PSAV能够预测具有提高的PSA值男性的前列腺活检

Prostate Cancer and P D:生殖细胞中 IL4、MGMT和AKT1变异与前列腺癌特异性死亡率相关

前列腺癌(PCa)是引起死亡的主要因素,并且遗传因素能够影响肿瘤的侵入性。一些生殖细胞变异已经被证明与PCa特异性死亡率(PCSM)相关,但是还需要进一步的重复证据。之前鉴定过的PCSM相关的22个遗传变异在7个群体中进行了基因分型(12082名病人;1544名PCa死亡)。对每一个群体,研究人员利用Cox比例风险模型来计算与每一个变异相关的PCSM风险的风险比和95%置信区间。之后,研究人员利用

Prostate Cancer P D:原发性肿瘤中p53状态可以预测阿比特龙和恩杂鲁胺在去势难治性前列腺癌中的疗效

最近,有研究人员测试了是否在原发性肿瘤中,基于组织的p53和PTEN基因组状态能够预测阿比特龙和恩杂鲁胺在去势难治性前列腺癌(CRPC)中的敏感性。研究人员进行了一项回顾性的分析,包括了309名患有CRPC且接受阿比特龙或恩杂鲁胺治疗的连续性病人。在这些病人中,101名男性(33%)具有可以用于分析的原发性肿瘤组织。研究人员利用基因验证免疫组织化学分析筛选了有害的TP53错义突变和PTEN缺失,并